The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation• Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?• Breathing Engineered Bacteria: A New Approach to Treating Lung Disease• Vedanta Biosciences Secures $60 Million in Funding Ahead of Pivotal Phase 3 Data• Gut fungi may hold the key to treating Asthma worldwide•

Category: Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations
Clinical & Manufacturing

Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations

FEB 20, 2025
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
Clinical & Manufacturing

Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

JAN 27, 2025
MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study
Clinical & Manufacturing

MaaT Pharma Announces Positive Results from Pivotal Phase 3 ARES Study

JAN 8, 2025
Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer
Clinical & Manufacturing

Microbio Announces Promising Results of “MS-20” in Combination with Keytruda for Non-Small Cell Lung Cancer

DEC 17, 2024
IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality
Clinical & Manufacturing

IBT’s phase III study shows a significant reduction in the secondary endpoint, all-cause mortality

SEP 4, 2024
Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus
Clinical & Manufacturing

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus

SEP 1, 2024
EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b
Clinical & Manufacturing

EUDRACAP® Select for oral targeting of sensitive microbiome: a case from development of functional coated capsule to clinical trial phase 1b

JUN 6, 2024
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection
Clinical & Manufacturing

Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 Study for the Prevention of Recurrent C. diff Infection

MAY 22, 2024
SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients
Clinical & Manufacturing

SNIPR Biome receives funding from CARB-X for advancement of SNIPR001 into clinical trials in haematological cancer patients

APR 22, 2024
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002
Clinical & Manufacturing

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002

APR 16, 2024
EnteroBiotix Completes £27m Financing Round & Initiates Phase 2 Study in Patients with IBS
Clinical & Manufacturing

EnteroBiotix Completes £27m Financing Round & Initiates Phase 2 Study in Patients with IBS

APR 4, 2024